M14 and A375 NAMPT/GFP also displayed a relevant increase of the pentose phosphate pathway (PPP) rate and of the activity of the glucose-6-phosphate dehydrogenase (G6PD, rate-limiting enzyme in this pathway, Figure 1E), which was in line with recent observations made in BRAFi-resistant MM cells [18]. This evidence concerns the gene G6PD and Miyoshi myopathy.